Bringing K-Aesthetics to Australia: PharmaResearch Showcases REJURAN® at Aesthetics 2026

Following REJURAN®'s TGA approval in 2023, the company hosted scientific sessions and a clinical masterclass for Australian healthcare professionals.

GANGNEUNG, South Korea, Aug. 13, 2026 /PRNewswire/ -- PharmaResearch, the biopharmaceutical company behind REJURAN®, recently participated in Aesthetics 2026, an international aesthetic medicine symposium held in Sydney, Australia. The company delivered scientific presentations and clinical education programs focused on its flagship polynucleotide (PN)-based skin booster.

Aesthetics 2026 brings together dermatologists, plastic surgeons and aesthetic medicine professionals from across Australia to share clinical insights and discuss the latest advances in the field. Convened by internationally recognized plastic surgeon Dr. Steven Liew, the event has become a key forum for scientific exchange within Australia's aesthetic medicine community.

During the event, Dr. Liew expressed strong interest in REJURAN's growing body of clinical evidence and PharmaResearch's structured education programs for healthcare professionals. The discussions also covered potential future collaboration in areas such as the development of scientific content tailored to the needs of Australian patients and local clinical practice, as well as training programs for local healthcare professionals. Building on these discussions, PharmaResearch plans to expand its scientific partnerships with global key opinion leaders and foster long-term relationships with Australia's medical community.

PharmaResearch hosted scientific sessions on the clinical use of REJURAN, along with a dedicated REJURAN clinical masterclass. The sessions provided Australian healthcare professionals with case-based insights and clinical data, focusing on treatment planning and injection techniques tailored to individual patient needs and goals.

Leading Korean medical experts, including Dr. Nark-Kyoung Rho, director of Leaders Dermatology Clinic Cheongdam, and Dr. Ho Sung Choi, director of LIEUL Clinic Seoul, served as featured speakers. Drawing on cases from their own practices, they discussed individualized treatment strategies for skin barrier function, pigmentation and the periorbital area. They also shared practical guidance on applying REJURAN across a range of skin concerns and patient profiles, strengthening participants' understanding of its clinical applications.

A dedicated K-Session featuring Korean medical experts also examined the latest developments in Korean aesthetic medicine and shared insights gained from clinical practice in Korea. Moving beyond a general product introduction, the session focused on real-world treatment planning and injection techniques, further expanding scientific exchange between healthcare professionals in Korea and Australia.

"This event demonstrated REJURAN's growing presence in the global aesthetic medicine market, supported by its scientific foundation and clinical evidence," a PharmaResearch representative said. "We will continue to expand our scientific collaboration with global key opinion leaders and strengthen clinical education for Australian healthcare professionals."

REJURAN entered the Australian market in 2023 following its inclusion in the Australian Register of Therapeutic Goods as a Class III medical device. Since then, PharmaResearch has continued to provide clinical education and facilitate scientific exchange for Australian healthcare professionals, supporting the appropriate clinical use of REJURAN.

About PharmaResearch:

PharmaResearch is a pioneering biopharmaceutical company dedicated to enhancing the quality of life for humanity through regenerative medicine. Its diverse portfolio includes medicines, medical devices, cosmetics, and health supplements, all leveraging the core ingredients - DOT™ PDRN and DOT™ PN - which are protected by multiple patents. PharmaResearch is headquartered in Gangneung-si, Gangwon-do.

Learn more at https://pharmaresearch.com/en/

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Bringing K-Aesthetics to Australia: PharmaResearch Showcases REJURAN® at Aesthetics 2026

"Cruise Your Way" in the 2027 season | New itineraries on the Rhine & Danube

ROSTOCK, Germany, Aug. 13, 2026 /PRNewswire/ -- A-ROSA River Cruises has released the brochure for its 2027 anniversary season. Headed under the company's new claim, "Cruise Your Way", the digital brochure presents the 2027 river cruise programme, including 20 new itineraries on the Rhine and Danube, in a refreshed design. Developed specifically for international markets, it serves as both a product guide and a sales tool for travel partners.

Additionally, the brochure starts off a new chapter of the A-ROSA brand presence. To mark its 25th anniversary, the company is positioning itself stronger than ever as a modern premium river cruise brand, emphasising individuality and guest choice. Under the claim "Cruise Your Way", A-ROSA intends to stand for ultimate freedom and flexibility. The new brand identity reflects this ambition, presenting itself in a clear, inspiring and emotive look with a focus on personalised experiences, contemporary comfort and international appeal, whilst maintaining the trusted strengths that have defined A-ROSA for 25 years.

In line with this, A-ROSA is continuing to develop its portfolio throughout the anniversary year 2027, offering a diverse range of itineraries. A total of 20 new cruises on the Rhine and Danube guarantee greater variety and allow for more in-depth visits to the ports of call. A particular highlight is A-ROSA SENA sailing southwards on the Rhine for the first time ever. With Vienna and Duisburg, A-ROSA also offers guests new ports of departure with excellent infrastructure. Thanks to their central locations, these berths are easily accessible by all means of transport, whether by plane, train or car. The operator is also strengthening the quality of the onboard experience through its popular "Premium All Inclusive" fare, with add-on services such as the Drinks Package Plus underlining the importance of indulgence and personal choice.

The digital brochure has been designed to support individual guests and travel partners alike with interactive features including clickable itineraries, embedded links and videos. It is available in a consumer edition or a trade edition featuring dedicated contact information and sales resources for travel professionals. The new A-ROSA brochure "European River Cruises 2027" is accessible in digital format and available for download on the website at www.arosa-cruises.com/catalogue.  

About A-ROSA

A-ROSA is the creator of cruises with a difference that take in cities, towns and countryside along Europe's most beautiful rivers: Danube, Douro, Rhine/Main/Moselle, Rhône/Saône and Seine. The current fleet is made up of 15 ships, all of which combine the amenities of a hotel with the benefits of a cruise. On board, Premium All-Inclusive fare guests can enjoy varied buffets, a choice of high-quality drinks and access to the SPA-ROSA, which features a sauna, massage room and gym. The ships dock in central locations, close to the heart of European metropolises, renowned historical sites and famous cultural and natural attractions – providing unforgettable experiences. To ensure that the cruise is a hit with the whole family, there are generously sized cabins, a Kids Club and heated outdoor pools, as well as a programme to suit every guest's needs. The company's flagship is innovative A-ROSA SENA with a hybrid propulsion system and battery storage. A-ROSA is headquartered in Rostock/Germany.

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

A-ROSA anniversary brochure launches with new look